Votrient
NICE backs Pfizer’s drug for advanced kidney cancer
December 16, 2014Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo
UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …
‘More patients want Votrient’
April 2, 2014Research and Development, Sales and Marketing Cancer, GSK, Pfizer, Sutent, Votrient
GlaxoSmithKline is looking at patient satisfaction as a potential marketing tool for its kidney cancer drug Votrient, setting up a …
GSK seeks licence extensions
August 8, 2013Sales and Marketing Cervarix, EMA, GSK, Votrient
GlaxoSmithKline is seeking to extend the licences of two of its brands, Cervarix and Votrient, in a bid to extend …
Survival boost for Votrient in mRCC
October 2, 2012Research and Development, Sales and Marketing GSK, Nexavar, Pfizer, Sutent, Votrient
GlaxoSmithKline’s renal cell carcinoma drug Votrient has proved itself non-inferior to a bitter rival, Pfizer’s Sutent, in terms of progression-free …
GSK’s Votrient gains new licence
August 8, 2012Sales and Marketing GSK, NICE, Votrient, soft cell sarcoma
GlaxoSmithKline has gained a new European licence for its cancer pill Votrient adding to its renal cell carcinoma licence. The …
FDA approves GSK’s Votrient for new licence
April 30, 2012Sales and Marketing Cancer, FDA Approval, GSK, Votrient
The FDA has approved GlaxoSmithKline’s cancer pill Votrient for the treatment of a rare group of cancers – but has …
GSK’s patient access scheme for Votrient sways NICE
December 24, 2010Sales and Marketing GSK, GlaxoSmithKline, NICE, Votrient, pazopanib, rcc, renal cell carcinoma
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient in final draft guidance after the pharma company offered to implement a …
The renal cell carcinoma market: Votrient to challenge Sutent’s lead
November 25, 2010Sales and Marketing GSK, GlaxoSmithKline, Pfizer, Sutent, Votrient, rcc, renal cell carcinoma
After decades of no new medicines emerging to treat renal cell carcinoma, no fewer than five new drugs were approved …
GSK tipped to lead kidney cancer market
July 1, 2010Sales and Marketing Kidney cancer, Patorma, Votrient, rcc
GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …
GSK’s Votrient approved in Europe
June 16, 2010Sales and Marketing GlaxoSmithKline, Kidney cancer, Votrient
The European Commission has granted a conditional marketing authorisation for a GlaxoSmithKline drug that treats the most common form of …
Latest content
